29.31USD-0.20%Mkt Cap: 5.46B USDP/E: —Last update: 2026-05-26
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the Unit…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap5.46B USD
Enterprise Value9.95B USD
Revenue (TTM)1.14B USD
Gross Profit620.80M USD
Net Income (TTM)-296.80M USD
Revenue/Share6.168 USD
Last Price29.31 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees3.1K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)20.97
PEG—
EV/EBITDA-79.56
EV/Revenue8.74
P/S4.56
P/B5.17
EPS (TTM)-1.38
EPS (Forward)1.33
52W Range
16.2445% of range45.30
52W High45.30 USD
52W Low16.24 USD
Profitability
Gross Margin60.34%
Oper. Margin-16.32%
EBITDA Margin-10.98%
Profit Margin-28.85%
ROE-29.62%
ROA-17.12%
Growth
Revenue Growth56.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-100.20M USD
CapEx (TTM)28.60M USD
FCF Margin-4.90%
FCF Yield-1.02%
Net Debt-445.30M USD
Net Debt/EBITDA3.56
Balance Sheet
Debt/Equity0.41
Current Ratio2.13
Quick Ratio2.01
Book Value/Sh5.418 USD
Cash/Share2.247 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Target (Mean)55.39 USD
Target Range27.00 USD – 86.00 USD
# Analysts15
Ownership
Shares Out.185.74M
Float164.99M
Insiders1.31%
Institutions54.22%
Short Interest
Short Ratio7.7d
Short % Float23.37%
Short % Out.9.19%
Shares Short17.00M
Short (prev mo.)18.70M
Technical
SMA 5022.20 (+32.1%)
SMA 20026.10 (+12.3%)
Beta0.30
S&P 52W Chg28.31%
Avg Vol (30d)2.64M
Avg Vol (10d)2.35M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—